NEW YORK — Chimeric antigen receptor T-cell therapy confers better outcomes than autologous stem cell transplant to some patients with relapsed diffuse large B-cell lymphoma, but it may be premature to declare transplant obsolete in this setting, according to a debate at HemOnc Today New York.

Autologous stem cell transplantation has been the standard of care for patients with relapsed and primary refractory DLBCL since 1995.